For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
SPORE in Prostate Cancer

You are here

Developmental Research Program

Co-Leaders Dr. David M. Nanus, MD, and Dr. Paraskevi Giannakakou, Ph.D.

The Weill Cornell Medicine SPORE in Prostate Cancer Developmental Research Program (DRP) acknowledges that to achieve the over-arching goal of impacting patient care, the SPORE must develop and maintain a highly productive translational research program. The DRP is co-led by Drs. David M. Nanus, MD, and Paraskevi Giannakakou, Ph.D. The co-leaders have extensive experience in mentoring at every academic level and significant past and current involvement in critical cancer-related organizations that include the AACR, the PCF, and the NCI.

They have received numerous extramural grants from the NCI, the DOD, and/or the PCF and have vast experience in the peer-review process at the NIH, the DOD, and the PCF. Drs. Nanus and Giannakakou work closely with Drs. Rubin, Beltran, and Cantley from the Administrative Core to implement all Requests for Proposals (RFPs), and collaborate with members of the SPORE Internal Advisory Board (IAB) and the External Advisory Board (EAB) to evaluate proposals.

The objectives of the Developmental Research Program (DRP) are:

  1. to identify and provide funding for innovative research projects in PCa, each with the potential to evolve into translational/clinical studies with meaningful human endpoints;

  2. to provide funding to high-quality projects that complement and enhance the overall goals of the SPORE;

  3. to ensure there is a sustained stream of innovative translational research projects within the SPORE; and

  4. to develop a mechanism to identify and promote outstanding work from investigators at our Tri-institutional Campus, who may or may not have prior expertise in PCa research.

Specific Aims:

AIM 1: Identify promising areas of prostate cancer related translational research that may directly impact clinical practice, and solicit high-quality applications by publicizing across the Tri-Institutional campus the availability of pilot funding for translational prostate cancer research;

AIM 2: Select research projects worthy of funding using internal and external reviewers and based on specific criteria.  Final selection to be made by the SPORE Executive Committee chaired by the Co-Directors of the DRP;

AIM 3: Evaluate research project’s progress and accomplishments, including the possibility of transitioning to a full SPORE Project. A program designed in which promising pilot projects follow one of three courses: funding for another year, elevation to a full SPORE project, or encouragement to apply for research support outside of the SPORE mechanism (NIH, DOD, PCF, etc.);

AIM 4: Evaluate the DRP program and work with the DRP investigators and the SPORE to assist them in achieving their translational research goals, including yearly evaluation of all DRP project progress reports.